Skip to content
Bored Studies
Recruiting

Study Evaluating the Safety and Efficacy of an ECM Hydrogel for the Treatment of Anorectal Fistulas

ECM Therapeutics, Inc. · NCT07035925

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
10
US sites recruiting
2
Study start
November 24, 2025
Record last updated
March 31, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Safety and Efficacy of ECMT-100 for the Treatment of Anorectal Fistulas

Being studied: ECMT-100

Conditions: Fistula in Ano

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male and female subjects at least 18 years of age.
  • Provide informed consent
  • Non-pregnant females
  • Clinical diagnosis of 1 high transsphincteric anorectal fistula, with 1 internal opening and 1-2 external openings, with a single seton in place.
  • Seton placement for a minimum of four (4) weeks
  • Willingness to participate in post-operative follow-up evaluations.

Exclusion Criteria

  • Inability to provide informed consent.
  • Medical history of Crohn's disease/Ulcerative Colitis.
  • Subjects with multiple fistula tracts (defined as >1 internal opening and/or >2 external openings), secondary tracts, horseshoe fistulas, J-pouch fistulas, superficial fistulas, ano/recto-vaginal fistulas or rectourethral fistulas.
  • Previous fistulotomy/fistulectomy at the target treatment site (a history of these procedures at other locations is not exclusionary).
  • Fistula of traumatic origin including obstetric.
  • Evidence of ongoing local infection.
  • Evidence of active abscess at the time of treatment.
  • Chronic disease such as congestive heart failure, liver disease, renal disease, insulin dependent diabetes (as determined by A1C reading from past 6-12 months), or any chronic illness that may interfere with participation in this study.
  • Active and unstable disease state or infection anywhere in the body per Investigator's evaluation and determination.
  • Autoimmune disease that is not stable.
  • Subjects who are immunocompromised such as known human immunodeficiency virus (HIV) or currently receiving chemotherapy or radiation therapy.
  • Ongoing use of antiplatelet drugs. Subjects may be included in the study if antiplatelet drugs have been stopped for 5 to 7 days prior to surgery.
  • Known coagulopathy (demonstrated by stated or medical record history of diagnosis)
  • Pregnancy
  • Previous history of radiation therapy in the area of the fistula.
  • History of collagen disease.
  • Known allergy to porcine products.
  • Religious objection to use of porcine products.

Recruiting US locations

  • Dartmouth Hitchcock Medical Center

    Lebanon, NH 03756

    Site contact: Madison Duclos · 603-653-3607

  • University of Pittsburgh Medical Center

    Pittsburgh, PA 15237

    Site contact: Kim Sainiak · 412-647-1705 · sainiakks@upmc.edu

Study contacts (from the official record)

  • Julie Cramer · 330-507-0801 · julie@clinicalresearchstrategies.com
  • Cynthia Berringer · 412-638-9986 · cberringer@ecmtherapeutics.com
Study Evaluating the Safety and Efficacy of an ECM Hydrogel for… (NCT07035925) | Bored Studies